RnRMarketResearch.com adds “Hyperuricemia – Pipeline Review, H1 2015” to its store. The provides an overview of the Hyperuricemia’s therapeutic pipeline.
DALLAS, June 4, 2015 /PRNewswire-iReach/ — The report “Hyperuricemia – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Hyperuricemia , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Hyperuricemia with 25 market data tables and 14 figures, spread across 63 pages is available at http://www.rnrmarketresearch.com/hyperuricemia-pipeline-review-h1-2015-market-report.html .
Photo – http://photos.prnewswire.com/prnh/20150604/220824
Hyperuricemia is an excess of uric acid in the blood. Uric acid is a breakdown product of purines that are part of many foods we eat. While hyperuricemia may indicate an increased risk of gout , the relationship between hyperuricemia and gout is unclear. This report also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects.
Companies discussed in this Hyperuricemia – Pipeline Review, H1 2015 report include: AstraZeneca PLC, CymaBay Therapeutics, Inc., Kissei Pharmaceutical Co., Ltd., LG Life Sciences, Ltd., Nippon Chemiphar Co., Ltd., Polaris Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited.
Drugs profiles discussed in this report includes arhalofenate, febuxostat, febuxostat XR, JPH-367, KGO-2142, KGO-2173, KUX-1151, LC-350189, NC-2500, pegadricase, RDEA-3170, Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia, Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia, XEN-102. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=388743 . (This is a premium report priced at US$2000 for a single user License.)
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Featured News & Press Releases cover by this report includes: Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat; Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric; Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat; Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat; Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea; May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan; Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67; Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan; Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
List of Tables
Number of Products under Development for Hyperuricemia, H1 2015 8
Number of Products under Development for Hyperuricemia – Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Hyperuricemia – Pipeline by AstraZeneca PLC, H1 2015 17
Hyperuricemia – Pipeline by CymaBay Therapeutics, Inc., H1 2015 18
Hyperuricemia – Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 19
Hyperuricemia – Pipeline by LG Life Sciences, Ltd., H1 2015 20
Hyperuricemia – Pipeline by Nippon Chemiphar Co., Ltd., H1 2015 21
Hyperuricemia – Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 22
Hyperuricemia – Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 23
Hyperuricemia – Pipeline by Teijin Pharma Limited, H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Hyperuricemia Therapeutics – Recent Pipeline Updates, H1 2015 51
Hyperuricemia – Dormant Projects, H1 2015 54
Hyperuricemia – Discontinued Products, H1 2015 55
List of Figures
Number of Products under Development for Hyperuricemia, H1 2015 8
Number of Products under Development for Hyperuricemia – Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 27
Number of Products by Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31
Number of Products by Top 10 Molecule Types, H1 2015 32
Number of Products by Stage and Top 10 Molecule Types, H1 2015 33
Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research
Comments